Academic Content and Language Evaluation of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9761)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jan 27, 2022 (publication date) through Nov 2, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Biological Chemistry
ISSN
1949-8454
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Muromoto R, Oritani K, Matsuda T. Current understanding of the role of tyrosine kinase 2 signaling in immune responses. World J Biol Chem 2022; 13(1): 1-14 [PMID: 35126866 DOI: 10.4331/wjbc.v13.i1.1] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8454/full/v13/i1/1.htm |
| Number | Citing Articles |
| 1 |
Mohamed E. Shaker, Hesham A.M. Gomaa, Mohamed A. Abdelgawad, Mohamed El-Mesery, Ahmed A. Shaaban, Sara H. Hazem. Emerging roles of tyrosine kinases in hepatic inflammatory diseases and therapeutic opportunities. International Immunopharmacology 2023; 120: 110373 doi: 10.1016/j.intimp.2023.110373
|
| 2 |
Yu Zhou, Xin Li, Ru Shen, Xiangzhu Wang, Fan Zhang, Suxing Liu, Di Li, Jian Liu, Puhui Li, Yinfa Yan, Ping Dong, Zhigao Zhang, Heping Wu, Linghang Zhuang, Rasheduzzaman Chowdhury, Matthew Miller, Mena Issa, Yuchang Mao, Hongli Chen, Jun Feng, Jing Li, Chang Bai, Feng He, Weikang Tao. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.884399
|
| 3 |
Abdulaziz M. Eshaq, Thomas W. Flanagan, Sofie-Yasmin Hassan, Sara A. Al Asheikh, Waleed A. Al-Amoudi, Simeon Santourlidis, Sarah-Lilly Hassan, Maryam O. Alamodi, Marcelo L. Bendhack, Mohammed O. Alamodi, Youssef Haikel, Mossad Megahed, Mohamed Hassan. Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance. Cancers 2024; 16(15): 2754 doi: 10.3390/cancers16152754
|
| 4 |
N. Pudjihartono, D. Ho, E. Golovina, T. Fadason, A.W. Kempa-Liehr, J.M. O’Sullivan. Juvenile idiopathic arthritis-associated genetic loci exhibit spatially constrained gene regulatory effects across multiple tissues and immune cell types. Journal of Autoimmunity 2023; 138: 103046 doi: 10.1016/j.jaut.2023.103046
|
| 5 |
Sarah Elyoussfi, Shraddha S Rane, Steve Eyre, Richard B Warren. TYK2 as a novel therapeutic target in psoriasis. Expert Review of Clinical Pharmacology 2023; 16(6): 549 doi: 10.1080/17512433.2023.2219054
|
| 6 |
David Bitterman, Paras Patel, Jennifer Y. Wang, Margaret Kabakova, Kayla Zafar, Austin Lee, Jessica Mineroff Gollogly, Marc Cohen, Evan Austin, Jared Jagdeo. Systematic review of dupilumab safety and efficacy for treatment of keloid scars. Archives of Dermatological Research 2024; 316(8) doi: 10.1007/s00403-024-03277-6
|
| 7 |
Jethendra Kumar Muruganantham, Ramakrishnan Veerabathiran. Genetic Basis for Mucormycosis Progression in COVID-19 Patients: From Susceptibility to Severity. Infectious Diseases & Immunity 2024; doi: 10.1097/ID9.0000000000000115
|
| 8 |
Kateryna Kozak, Halyna Pavlyshyn, Oleksandr Kamyshnyi, Oksana Shevchuk, Mykhaylo Korda, Sandor G. Vari. The Relationship between COVID-19 Severity in Children and Immunoregulatory Gene Polymorphism. Viruses 2023; 15(10): 2093 doi: 10.3390/v15102093
|
| 9 |
Vanessa L. Kronzer, Jeffrey A. Sparks, Soumya Raychaudhuri, James R. Cerhan. Low-frequency and rare genetic variants associated with rheumatoid arthritis risk. Nature Reviews Rheumatology 2024; 20(5): 290 doi: 10.1038/s41584-024-01096-7
|
| 10 |
Carmen Mestre-Durán, Carla Martín-Cortázar, Blanca García-Solís, Alicia Pernas, Lidia Pertíñez, Víctor Galán, Luisa Sisinni, Laura Clares-Villa, Alfonso Navarro-Zapata, Karima Al-Akioui, Adela Escudero, Cristina Ferreras, Antonio Pérez-Martínez. Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells. Frontiers in Immunology 2023; 13 doi: 10.3389/fimmu.2022.1045316
|
| 11 |
Yelei Gao, Ya Wang, Lina Zhou, Ge Lv, Jie Yu, Luying Zhang, Yan Meng, Wenli He, Ran Chen, Xiaodong Zhao, Ying Dou. Successful Immune Reconstitution in a Patient with a TYK2 Deficiency after Allogeneic Stem Cell Transplantation from Unrelated Donors. Journal of Clinical Immunology 2024; 44(7) doi: 10.1007/s10875-024-01753-2
|
| 12 |
Dante Dahabreh, Seungyeon Jung, Yael Renert-Yuval, Jonathan Bar, Ester Del Duca, Emma Guttman-Yassky. Alopecia Areata: Current Treatments and New Directions. American Journal of Clinical Dermatology 2023; 24(6): 895 doi: 10.1007/s40257-023-00808-1
|
| 13 |
Alexey Sarapultsev, Evgenii Gusev, Maria Komelkova, Irina Utepova, Shanshan Luo, Desheng Hu. JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions. Molecular Biomedicine 2023; 4(1) doi: 10.1186/s43556-023-00151-1
|
| 14 |
Eunsun Park, Seolhee Park, Sun Joo Lee, Dayeon Jeong, Hee Jin, Heegyum Moon, Boksik Cha, Dayea Kim, Seonghee Ma, Wonhyo Seo, Seung-Hee Han, Yun-Sil Lee, Soosung Kang. Identification and Biological Evaluation of a Potent and Selective JAK1 Inhibitor for the Treatment of Pulmonary Fibrosis. Journal of Medicinal Chemistry 2023; 66(23): 16342 doi: 10.1021/acs.jmedchem.3c01712
|
| 15 |
Yasmin Zurba, Beatriz Gros, Mohammad Shehab. Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review. Biomedicines 2023; 11(3): 747 doi: 10.3390/biomedicines11030747
|
| 16 |
Kuojun Zhang, Ke Ye, He Tang, Zhihao Qi, Tianyu Wang, Jie Mao, Xiangyu Zhang, Sheng Jiang. Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors. Journal of Medicinal Chemistry 2023; 66(7): 4378 doi: 10.1021/acs.jmedchem.2c01800
|
| 17 |
Thu Minh Truong, Gaurav N. Pathak, Amit Singal, Viktoriia Taranto, Babar K. Rao. Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis. Annals of Pharmacotherapy 2024; 58(4): 416 doi: 10.1177/10600280231153863
|
| 18 |
Parinaz Javanbakht, Farzane Rezaei Yazdi, Fatemeh Taghizadeh, Farnaz Khadivi, Hatef Ghasemi Hamidabadi, Iraj Ragerdi Kashani, Davood Zarini, Sina Mojaverrostami. Quercetin as a possible complementary therapy in multiple sclerosis: Anti-oxidative, anti-inflammatory and remyelination potential properties. Heliyon 2023; 9(11): e21741 doi: 10.1016/j.heliyon.2023.e21741
|
| 19 |
Gretchen D Ball, Alexandra Golant. A Case of Extensive Lichen Planus Treated With Deucravacitinib. Cureus 2024; doi: 10.7759/cureus.71951
|
| 20 |
Kriti Khare, Rajesh Pandey. Cellular heterogeneity in disease severity and clinical outcome: Granular understanding of immune response is key. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.973070
|
| 21 |
Martina Dragotto, Martina D’Onghia, Emanuele Trovato, Linda Tognetti, Pietro Rubegni, Laura Calabrese. Therapeutic Potential of Targeting the JAK/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition. Journal of Clinical Medicine 2024; 13(11): 3091 doi: 10.3390/jcm13113091
|
| 22 |
Ryuta Muromoto, Kenji Oritani, Tadashi Matsuda. Role of tyrosine kinase 2 signals during progression of psoriasis. Exploration of Immunology 2022; : 760 doi: 10.37349/ei.2022.00081
|
| 23 |
Fatima Barmania, Juanita Mellet, Megan A. Holborn, Michael S. Pepper. Application of Omic Techniques to Identify New Biomarkers and Drug Targets for COVID-19. Advances in Experimental Medicine and Biology 2023; 1412: 119 doi: 10.1007/978-3-031-28012-2_6
|